Table 1.
Results of In Vivo Efficacy Studies in Syrian Golden Hamsters
| f-CNT-AmB |
Miltefosine | AmBisome | ||||||
| Drug, Route, and Dose | 30 Days Postinfection (n = 7) | Control (n = 8) | IP 5 mg/kg (n = 11) | OL 5 mg/kg (n = 8) | OL 10 mg/kg (n = 7) | OL 15 mg/kg (n = 8) | OL 5 mg/kg (n = 8) | IP 5 mg/kg (n = 11) |
| Amastigotes/500 nuclei | 580.8 ± 26.6 | 615.5 ± 15.2 | 26.2 ± 7.3 | 57.7 ± 5.8 | 20.2 ± 2.2 | 10.8 ± 2.9 | 113.6 ±13.8 | 13.8 ± 5.3 |
| % inhibition in spleen | … | … | 95.5 ± 1.2 | 90.2 ± 0.2 | 96.6 ± 0.4 | 98.2 ± 0.5 | 80.6 ± 2.3 | 97.6 ± 0.9 |
| % suppression in parasite replication | … | … | 95.7 ± 1.2 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 97.7 ± 0.8 |
| Parasite burden, LDUa | 1225.3 ± 63.1 | 1583.5 ± 44.6 | 32.2 ± 9.2 | 71.1 ± 9.2 | 34.3 ± 7.1 | 14.9 ± 6.7 | 188.9 ± 88.9 | 16.4 ± 6.3 |
Data are expressed as mean ± standard deviation.
Abbreviations: AmB, amphotericin B; f-CNT, functionalized carbon nanotubes; IP, intraperitoneal; LDU, Leishman-Donovan unit; OL, oral.
a
LDU = number of amastigotes per 500 nuclei × tissue weight (mg).